INT204002

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2007
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 15
Total Number 18
Disease Relevance 8.57
Pain Relevance 0.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Gsk3b) carbohydrate metabolic process (Gsk3b) protein complex (Gsk3b)
response to stress (Gsk3b) cytoplasm (Gsk3b) cytosol (Gsk3b)
Anatomy Link Frequency
neurons 2
Gsk3b (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 20 97.84 Very High Very High Very High
Dopamine 17 97.20 Very High Very High Very High
tolerance 58 96.96 Very High Very High Very High
Hippocampus 20 96.64 Very High Very High Very High
Eae 121 73.72 Quite High
antidepressant 23 62.48 Quite High
depression 44 57.44 Quite High
Serotonin 3 55.04 Quite High
corticosteroid 15 41.56 Quite Low
Pyramidal cell 4 16.00 Low Low
Disease Link Frequency Relevance Heat
Targeted Disruption 494 100.00 Very High Very High Very High
Aggression 13 100.00 Very High Very High Very High
Parkinson's Disease 40 99.58 Very High Very High Very High
Shock 97 99.30 Very High Very High Very High
Impaired Glucose Tolerance 43 97.60 Very High Very High Very High
Repression 20 95.16 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 45 94.24 High High
Manic Depressive Disorder 105 93.68 High High
Sprains And Strains 108 93.16 High High
Death 37 91.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In parallel with the A1.4 and A1.6 RNA samples, protein extracts were harvested at 0, 4, 24, 36 and 48 hours following the serum shock, in order to monitor the relative reduction in levels of GSK3 expression in the two clones (Fig. 4).
Negative_regulation (reduction) of Gene_expression (expression) of GSK3 associated with shock
1) Confidence 0.55 Published 2007 Journal J Circadian Rhythms Section Body Doc Link PMC1803776 Disease Relevance 0.48 Pain Relevance 0
The ~4 hr lengthening in mPer2 transcription in the c2.1 cell line, which is 75% deficient in GSK3 expression most resembles the ~4 hr mPer2 transcriptional lengthening observed with the previously characterized A1.4 line which exhibited a similar level of GSK3?
Negative_regulation (deficient) of Gene_expression (expression) of GSK3
2) Confidence 0.41 Published 2007 Journal J Circadian Rhythms Section Body Doc Link PMC1803776 Disease Relevance 0.33 Pain Relevance 0
Therefore, the targeted "knock down" of the GSK3?
Negative_regulation (down) of Gene_expression (knock) of GSK3 associated with targeted disruption
3) Confidence 0.40 Published 2007 Journal J Circadian Rhythms Section Body Doc Link PMC1803776 Disease Relevance 0.10 Pain Relevance 0
In a setting where the circadian clock mechanism, within a functional range, is relatively insulated from reduction in absolute levels of GSK3, the absence of GSK3?
Negative_regulation (reduction) of Gene_expression (levels) of GSK3
4) Confidence 0.40 Published 2007 Journal J Circadian Rhythms Section Body Doc Link PMC1803776 Disease Relevance 0.13 Pain Relevance 0
However, by TP48, at which A1.4 and A1.6 both have comparable levels of residual GSK3 expression, a delay of ~8 hrs is observed with both clones, with a peak occurring at TP52 (Fig. 3A,B).


Negative_regulation (levels) of Gene_expression (expression) of GSK3
5) Confidence 0.40 Published 2007 Journal J Circadian Rhythms Section Body Doc Link PMC1803776 Disease Relevance 0.39 Pain Relevance 0
, where in a 72 hr time span, a 50% reduction in GSK3 levels may still be sufficient to fully carry out the enzyme's functional duties.
Negative_regulation (reduction) of Gene_expression (levels) of GSK3
6) Confidence 0.40 Published 2007 Journal J Circadian Rhythms Section Body Doc Link PMC1803776 Disease Relevance 0.09 Pain Relevance 0
These observations indicate significant disruption in territorial aggression in the GSK-3?
Negative_regulation (disruption) of Gene_expression (aggression) of GSK-3 associated with aggression
7) Confidence 0.39 Published 2009 Journal Mol Brain Section Body Doc Link PMC2785804 Disease Relevance 0.56 Pain Relevance 0.13
KO mice are partly caused by the reduced phosphorylation levels of Akt and GSK3?.
Negative_regulation (reduced) of Gene_expression (levels) of GSK3 associated with targeted disruption
8) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2956634 Disease Relevance 0.37 Pain Relevance 0.03
These decreases in levels of phosphorylated Akt and GSK3?
Negative_regulation (decreases) of Gene_expression (levels) of GSK3
9) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2956634 Disease Relevance 0.93 Pain Relevance 0.08
KO mice, we assessed the phosophorylation levels of Akt and GSK3?
Negative_regulation (assessed) of Gene_expression (levels) of GSK3 associated with targeted disruption
10) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2956634 Disease Relevance 1.28 Pain Relevance 0.20
However, the phosphorylation levels of Akt (Ser473) and GSK3?
Negative_regulation (However) of Gene_expression (levels) of GSK3
11) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2956634 Disease Relevance 0.74 Pain Relevance 0.09
We speculated that hepatic deletion of GSK-3?
Negative_regulation (hepatic) of Gene_expression (deletion) of GSK-3
12) Confidence 0.33 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3017066 Disease Relevance 1.02 Pain Relevance 0.04
Selective loss of GSK-3?
Negative_regulation (loss) of Gene_expression (Selective) of GSK-3
13) Confidence 0.33 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3017066 Disease Relevance 0.91 Pain Relevance 0.13
Since there was a lack of insulin-sensitization in the tissue-specific deletions of GSK-3?
Negative_regulation (lack) of Gene_expression (deletions) of GSK-3
14) Confidence 0.33 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3017066 Disease Relevance 0.29 Pain Relevance 0
Hence, we addressed the question of whether GSK3?
Spec (whether) Negative_regulation (addressed) of Spec (whether) Gene_expression (question) of GSK3
15) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2797305 Disease Relevance 0 Pain Relevance 0
is a negative regulator of Bmal1 transcription, it can be expected that when GSK3?
Negative_regulation (regulator) of Gene_expression (expected) of GSK3
16) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2797305 Disease Relevance 0.19 Pain Relevance 0.03
However, in our study, we show that, in vivo, MPTP treatment induces a progressive loss of TH-positive neurons concomitant with an increase of phospho-Tyr216 GSK-3?
Negative_regulation (loss) of Gene_expression (progressive) of GSK-3 in neurons associated with parkinson's disease
17) Confidence 0.15 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2675062 Disease Relevance 0.75 Pain Relevance 0
We observed that inhibiting GSK3?
Negative_regulation (inhibiting) of Gene_expression (observed) of GSK3
18) Confidence 0.07 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2877100 Disease Relevance 0 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox